• <nav id="ycwek"></nav>
  • <menu id="ycwek"><tt id="ycwek"></tt></menu>
    <nav id="ycwek"><strong id="ycwek"></strong></nav>
  • Market Overview

    Why This Biogen Analyst Says The FDA Could Still Approve Aducanumab

    Share:
    Why This Biogen Analyst Says The FDA Could Still Approve Aducanumab

    Biogen Inc (NASDAQ: BIIB) shares are retreating sharply after an Adcom committee recommended against approval of its investigational Alzheimer's drug aducanumab.

    Despite the setback, an analyst at SVB Leerink said aducanumab could still successfully clear the final FDA hurdle.

    The Biogen Analyst: Analyst Marc Goodman maintained an Outperform rating on Biogen and lowered the price target from $402 to $382.

    The Biogen Thesis: A good chance exists that the FDA will approve aducanumab anyway, Goodman said in a note, naming four reasons why. 

    First, SVB Leerink's key opinion leader commentary prepared the sell-side firm for a negative FDA panel, given the conservative approach of committee members the analyst said.

    The key opinion leader Goodman spoke with said the drug could be approved anyway, he said. 

    Second, there have never been FDA briefing documents that were so blatantly obvious about the FDA's positive view, Goodman said.

    Related Link: The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions

    Third, committee members seemed so upset with the FDA's views in those briefing docs that the members didn't really answer the first question the FDA asked regarding whether the Phase 3 EMERGE study on its own can be viewed as a positive study, the analyst said.

    Even the key opinion leaders SVB Leerink interacted in the past year who were against approval considered the study to be positive, he said. 

    Finally, Billy Dunn, director of the FDA's office of neuroscience, who is pushing for approval, remained passive during the combative Adcom discussions, Goodman said.

    It as if Dunn was not as concerned about the panel agreeing with the FDA's positive view, the analyst said. 

    Following the negative Adcom outcome, SVB Leerink lowered  its probability of success for aducanumab from 80% to 70% to acknowledge the higher risk profile.

    BIIB Price Action: At last check, Biogen shares were slumping 29.03% to $233.44. 

    Related Link: Attention Biotech Investors: Mark Your Calendar For These November PDUFA Dates

    Latest Ratings for BIIB

    DateFirmActionFromTo
    Nov 2020RBC CapitalMaintainsSector Perform
    Nov 2020DZ BankUpgradesHoldBuy
    Nov 2020B of A SecuritiesDowngradesNeutralUnderperform

    View More Analyst Ratings for BIIB
    View the Latest Analyst Ratings

     

    Related Articles (BIIB)

    View Comments and Join the Discussion!

    Posted-In: Marc GoodmanAnalyst Color Biotech Price Target Reiteration Analyst Ratings Movers Trading Ideas Best of Benzinga

    Latest Ratings

    StockFirmActionPT
    CCSSusquehannaInitiates Coverage On54.0
    ZSWedbushMaintains185.0
    SNPSCredit SuisseMaintains265.0
    SNOWCredit SuisseMaintains265.0
    NACredit SuisseMaintains76.0
    View the Latest Analytics Ratings
    Don't Miss Any Updates!
    News Directly in Your Inbox
    Subscribe to:
    Benzinga Premarket Activity
    Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
    Market in 5 Minutes
    Everything you need to know about the market - quick & easy.
    Fintech Focus
    A daily collection of all things fintech, interesting developments and market updates.
    Thank You

    Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

    4887王中王鉄算盘开奖结小说